Starry(SH:603520) Xin Lang Cai Jing·2025-09-15 01:52Core Viewpoint - The stock of Zhejiang Sitaili Pharmaceutical Co., Ltd. experienced a 6.12% increase, reaching 12.65 CNY per share, with a total market capitalization of 5.546 billion CNY as of September 15 [1] Group 1: Company Overview - Zhejiang Sitaili Pharmaceutical Co., Ltd. was established on September 15, 1997, and went public on March 9, 2016 [1] - The company specializes in the production and sales of non-ionic iodine contrast agent raw materials and quinolone raw materials [1] - The revenue composition of the company includes: contrast agents 79.73%, other supplementary products 10.19%, other 6.16%, CMO/CDMO 2.41%, and quinolone series 1.52% [1] Group 2: Fund Holdings - One fund, Xingye Healthcare A (011466), holds a significant position in Sitaili, with 1.8991 million shares, accounting for 4.83% of the fund's net value, making it the sixth-largest holding [2] - The fund has achieved a year-to-date return of 36.14% and a one-year return of 49.23%, ranking 1872 out of 8246 and 3177 out of 8054 in its category, respectively [2] - The fund manager, Chen Xu, has been in position for 4 years and 193 days, with a total fund size of 385 million CNY [2]